CARA - Cara Therapeutics Inc Stock Price, Fair Value and News

0.75USD-0.06 (-7.41%)Delayed

Market Summary

USD0.75-0.06

Delayed

-7.41%

CARA Stock Price

View Fullscreen

CARA RSI Chart

CARA Valuation

Market Cap

41.0M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

2.42

EV/EBITDA

0.09

Price/Free Cashflow

-0.45

CARA Price/Sales (Trailing)

CARA Profitability

EBT Margin

-504.63%

Return on Equity

-411.18%

Return on Assets

-136.01%

Free Cashflow Yield

-220.18%

CARA Fundamentals

CARA Revenue

Revenue (TTM)

16.9M

Rev. Growth (Yr)

-65.37%

Rev. Growth (Qtr)

-28.93%

CARA Earnings

Earnings (TTM)

-122.5M

Earnings Growth (Yr)

-15.12%

Earnings Growth (Qtr)

5.07%

Breaking Down CARA Revenue

Last 7 days

4.2%

Last 30 days

2.7%

Last 90 days

19.1%

Trailing 12 Months

-80.5%

How does CARA drawdown profile look like?

CARA Financial Health

Current Ratio

5.38

CARA Investor Care

Shares Dilution (1Y)

1.28%

Diluted EPS (TTM)

-2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.9M	0	0	0
2023	43.2M	27.2M	21.2M	21.0M
2022	36.0M	48.9M	39.4M	41.9M
2021	107.1M	79.1M	51.0M	23.0M
2020	23.6M	24.0M	27.5M	135.1M
2019	17.9M	20.2M	20.9M	19.9M
2018	0	2.9M	7.9M	13.5M
2017	361.0K	636.0K	911.0K	911.0K
2016	0	2.6M	1.3M	86.0K
2015	3.5M	3.4M	4.7M	3.8M
2014	9.8M	7.6M	5.4M	3.2M
2013	0	4.8M	8.4M	12.0M
2012	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cara Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	posner christopher	sold	-2,952	0.75	-3,936	president and ceo
Apr 05, 2024	terrillion scott	sold	-2,284	0.83	-2,753	sec'y; chief compliance & g.c.
Apr 05, 2024	goncalves joana	sold	-2,284	0.83	-2,753	chief medical officer
Feb 29, 2024	terrillion scott	sold	-2,930	0.89	-3,293	sec'y; chief compliance & g.c.
Feb 29, 2024	posner christopher	sold	-5,192	0.89	-5,834	president and ceo
Feb 29, 2024	goncalves joana	sold	-2,930	0.89	-3,293	chief medical officer
Feb 08, 2024	posner christopher	sold	-18,854	0.53	-35,575	president and ceo
Feb 01, 2024	posner christopher	sold	-2,739	0.55	-4,981	president and ceo
Feb 01, 2024	terrillion scott	acquired	-	-	13,500	sec'y; chief compliance & g.c.
Feb 01, 2024	menzaghi frederique ph.d.	acquired	-	-	13,500	chief scientific off,svp-r&d

Which funds bought or sold CARA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	B. Riley Wealth Advisors, Inc.	reduced	-9.75	47,677	93,489	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-31.01	-887	4,833	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-69,385	-	-%
May 16, 2024	COMERICA BANK	unchanged	-	6.00	36.00	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	41.66	255,149	602,269	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-517,773	-	-%
May 15, 2024	FARALLON CAPITAL MANAGEMENT LLC	unchanged	-	259,894	1,416,190	0.01%
May 15, 2024	STATE STREET CORP	reduced	-1.76	154,176	912,688	-%
May 15, 2024	Tudor Investment Corp Et Al	unchanged	-	15,551	84,736	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-28,669	-	-%

Are Funds Buying or Selling CARA?

Are funds buying CARA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CARA

No. of Funds

Unveiling Cara Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	bain capital life sciences opportunities iii, lp	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	4.83%	2,631,067	SC 13G/A
Jan 29, 2024	blackrock inc.	6.5%	3,554,258	SC 13G/A
Jul 25, 2023	vifor (international) ltd	13.7%	7,396,770	SC 13G/A
Jul 07, 2023	blackrock inc.	6.9%	3,701,968	SC 13G/A
Feb 09, 2023	vanguard group inc	5.77%	3,101,724	SC 13G/A
Jan 26, 2023	blackrock inc.	14.4%	7,730,529	SC 13G/A
Jan 20, 2023	blackrock inc.	14.4%	7,730,529	SC 13G/A
Nov 18, 2022	bain capital life sciences opportunities iii, lp	5.0%	2,696,030	SC 13G
Feb 15, 2022	first manhattan co	0.0%	0	SC 13G/A

Recent SEC filings of Cara Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 06, 2024	4	Insider Trading
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to Cara Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cara Therapeutics Inc News

Latest updates

Cara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-28.9%	2,135,000	3,004,000	4,866,000	6,933,000	6,165,000	3,261,000	10,813,000	23,003,000	4,790,000	821,000	20,272,000	50,877,667	81,483,333	112,089,000	9,266,000	5,634,000	8,093,000	4,511,000	5,785,000	5,208,000	4,382,000
Operating Expenses	-10.7%	31,801,000	35,611,000	33,764,000	39,273,000	33,815,000	34,568,000	34,658,000	27,475,000	32,701,000	34,343,000	21,396,000	30,876,000	25,496,000	33,799,000	26,286,000	31,518,000	38,094,000	34,481,000	40,218,000	29,350,000	27,516,000
S&GA Expenses	-100.0%	-	6,588,000	6,755,000	7,545,000	6,891,000	6,428,000	6,912,000	7,570,000	9,347,000	11,512,000	5,882,000	5,651,000	6,365,000	6,659,000	5,219,000	5,410,000	4,558,000	4,617,000	4,226,000	4,994,000	3,908,000
R&D Expenses	-22.7%	21,964,000	28,415,000	25,451,000	30,310,000	24,334,000	26,010,000	24,691,000	19,905,000	21,273,000	22,831,000	15,514,000	25,225,000	19,131,000	27,140,000	21,067,000	26,108,000	33,536,000	29,864,000	35,992,000	24,356,000	23,608,000
EBITDA Margin	-23.8%	-5.03	-4.06	-4.02	-3.14	-1.97	-2.04	-2.24	-1.80	-2.45	-3.83	0.47	0.10	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-255,000	-132,000	-182,000	-122,000	-166,000	-330,000	-235,000	-85,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-33,382,000	-1,013,000	-30,745,000	-23,301,000	78,654,000	-16,641,000	-25,250,000	-29,044,000	-28,777,000	-33,172,000	-23,195,000	-22,045,000
EBT Margin	-23.8%	-5.05	-4.08	-4.03	-3.15	-1.98	-2.04	-2.24	-1.81	-2.46	-3.84	0.46	0.10	-	-	-	-	-	-	-	-	-
Net Income	5.1%	-30,696,000	-32,337,000	-28,032,000	-31,479,000	-26,665,000	-30,339,000	-23,180,000	-4,206,000	-27,749,000	-33,382,000	-1,013,000	-30,745,000	-23,301,000	78,909,000	-16,509,000	-25,068,000	-28,922,000	-28,611,000	-32,842,000	-22,960,000	-21,960,000
Net Income Margin	-28.0%	-7.23	-5.65	-5.49	-4.11	-1.95	-2.04	-2.25	-1.36	-2.58	-3.84	0.47	0.11	-	-	-	-	-	-	-	-	-
Free Cashflow	-61.1%	-31,289,000	-19,422,000	-19,645,000	-20,445,000	-34,618,000	-23,510,000	-25,192,000	-4,503,000	-25,568,000	-1,412,000	-14,283,000	-21,172,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-28.4%	90.00	126	115	134	153	182	214	227	224	247	225	221	250	271	147	169	196	233	264	150	171
Current Assets	-30.1%	81.00	116	101	125	143	169	187	176	152	173	171	164	188	195	133	142	133	166	203	125	144
Cash Equivalents	-6.3%	48.00	52.00	63.00	58.00	47.00	64.00	43.00	47.00	22.00	14.00	23.00	23.00	23.00	32.00	76.00	57.00	17.00	19.00	35.00	19.00	15.00
Inventory	-2.8%	3.00	3.00	3.00	3.00	4.00	2.00	2.00	3.00	2.00	3.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	6.8%	4.00	3.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-12.3%	60.00	69.00	-	-	-	23.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-41.0%	15.00	26.00	23.00	25.00	17.00	23.00	28.00	21.00	18.00	18.00	16.00	15.00	17.00	18.00	17.00	25.00	33.00	43.00	48.00	40.00	42.00
Shareholder's Equity	-47.8%	30.00	57.00	86.00	109	137	159	185	204	204	228	207	203	230	249	128	141	160	187	212	100	115
Retained Earnings	-4.5%	-715	-684	-652	-624	-592	-566	-535	-512	-508	-480	-447	-446	-415	-392	-471	-454	-429	-400	-372	-339	-316
Additional Paid-In Capital	0.5%	745	742	738	734	731	727	723	719	714	709	699	650	646	641	599	595	590	587	584	439	431
Shares Outstanding	0.3%	55.00	54.00	54.00	54.00	54.00	54.00	54.00	54.00	54.00	51.00	50.00	50.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	131	-	-	-	417	-	-	-	696	-	-	-	726	-	-	-	784	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-75.3%	-30,453	-17,370	-19,645	-20,445	-34,618	-23,510	-25,192	-4,503	-25,525	-1,245	-14,116	-21,005	-23,721	82,088	-21,620	-27,652	-38,303	-31,166	-25,637	-24,896	-27,526
Share Based Compensation	-7.1%	3,345	3,601	3,334	3,442	3,353	3,801	3,574	4,655	5,704	8,784	4,393	3,476	4,132	4,065	3,305	4,619	2,846	3,386	2,933	4,015	2,234
Cashflow From Investing	185.9%	25,951	-30,205	23,155	32,803	17,708	44,423	21,176	29,677	33,431	-53,581	14,433	20,528	13,869	-164,155	39,539	67,382	36,959	14,738	-96,881	25,228	26,399
Cashflow From Financing	-101.9%	-685	36,475	1,116	-	560	22.00	104	182	3.00	45,288	339	293	688	38,469	395	201	75.00	28.00	138,368	3,974	234

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CARA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 2,135	$ 6,165
Operating expenses:
Cost of goods sold	620	2,590
Research and development	21,964	24,334
General and administrative	6,816	6,891
Restructuring	2,401
Total operating expenses	31,801	33,815
Operating loss	(29,666)	(27,650)
Other income, net	952	985
Non-cash interest expense on liability related to sales of future royalties and milestones	(1,982)
Net loss	$ (30,696)	$ (26,665)
Net loss per share:
Basic	$ (0.56)	$ (0.49)
Diluted	$ (0.56)	$ (0.49)
Weighted average shares:
Basic	54,588,090	53,872,038
Diluted	54,588,090	53,872,038
Other comprehensive income, net of tax of $0:
Change in unrealized gains on available-for-sale marketable securities	$ 69	$ 571
Total comprehensive loss	(30,627)	(26,094)
Collaborative revenue
Revenue:
Total revenue	788	2,750
Commercial supply revenue
Revenue:
Total revenue	640	3,191
Royalty revenue
Revenue:
Total revenue		125
Clinical compound revenue
Revenue:
Total revenue	84	$ 99
Other revenue
Revenue:
Total revenue	$ 623

CARA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 46,996	$ 51,775
Marketable securities	22,777	48,983
Accounts receivable, net - related party	1,718	2,765
Inventory, net	2,741	2,821
Income tax receivable	697	697
Other receivables	506	555
Prepaid expenses	5,790	8,154
Restricted cash		408
Total current assets	81,225	116,158
Operating lease right-of-use assets	3,826	4,864
Property and equipment, net	3,548	3,322
Restricted cash, non-current	1,500	1,500
Total assets	90,099	125,844
Current liabilities:
Accounts payable and accrued expenses	14,875	25,592
Operating lease liability, current	220
Total current liabilities	15,095	25,592
Liability related to sales of future royalties and milestones, net	38,376	37,079
Operating lease liability, non-current	6,825	6,088
Total liabilities	60,296	68,759
Commitments and contingencies (Note 17)
Stockholders' equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023, zero shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock; $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023, 54,667,079 shares and 54,480,704 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	54	54
Additional paid-in capital	745,381	742,036
Accumulated deficit	(715,441)	(684,745)
Accumulated other comprehensive loss	(191)	(260)
Total stockholders' equity	29,803	57,085
Total liabilities and stockholders' equity	$ 90,099	$ 125,844

About Cara Therapeutics Inc

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

CEO	Mr. Christopher A. Posner
WEBSITE	caratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	106

Cara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cara Therapeutics Inc? What does CARA stand for in stocks?

CARA is the stock ticker symbol of Cara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cara Therapeutics Inc (CARA)?

As of Fri May 17 2024, market cap of Cara Therapeutics Inc is 41.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers. The fair value of Cara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CARA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CARA is over valued or under valued. Whether Cara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CARA.

What is Cara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CARA's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 2.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CARA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cara Therapeutics Inc's stock?

In the past 10 years, Cara Therapeutics Inc has provided -0.253 (multiply by 100 for percentage) rate of return.